Literature DB >> 24599757

Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort.

Afef Slimani1, Yahia Harira, Imen Trabelsi, Walid Jomaa, Faouzi Maatouk, Khaldoun Ben Hamda, Mohamed Naceur Slimane.   

Abstract

The association of E670G (rs505151) polymorphism in PCSK9 gene with an increased risk of coronary artery disease (CAD) and ischemic stroke (IS) was reported in previous studies. We investigated the effect of the E670G (rs505151) on the risk of CAD and IS in a Tunisian cohort. Genotyping of the PCSK9 E670G was performed using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) and then confirmed by direct sequencing. The frequency of the 670G allele was significantly higher in the CAD than in the no-CAD subgroup (0.132 vs. 0.068, p = 0.030). As expected, the incidence of E670G was significantly important in IS subgroup than control group (0.122 vs. 0.073, p = 0.032). Furthermore in CAD patients, the 670G carriers showed significantly increased plasma total cholesterol and LDL-cholesterol levels compared to E670 carriers (6.78 [6.47-7.00] vs. 4.92 [4.02-5.46] mmol/l, p < 0.0001 and 4.60 [4.00-5.04] vs. 3.00 [2.22-3.70] mmol/l p = 0.001, respectively). The risk and severity of CAD were significantly increased in 670G carriers between no-CAD subgroup and CAD patients presenting a stenosis ≥50 % in two or three major coronary arteries (0.068 vs. 0.198, p = 0.001, OR = 3.39 [1.55-7.37]). The E670G polymorphism of the PCSK9 gene is mainly associated with a increased risk and severity of CAD and IS in Tunisian cohort.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599757     DOI: 10.1007/s12031-014-0238-2

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  44 in total

1.  PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke.

Authors:  Estelle Rousselet; Jadwiga Marcinkiewicz; Jasna Kriz; Ann Zhou; Mary E Hatten; Annik Prat; Nabil G Seidah
Journal:  J Lipid Res       Date:  2011-04-25       Impact factor: 5.922

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 3.  Management of cardiovascular risk: the importance of meeting lipid targets.

Authors:  Antonio M Gotto; Jennifer E Moon
Journal:  Am J Cardiol       Date:  2012-07-01       Impact factor: 2.778

4.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Authors:  Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

5.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

Review 6.  Is type 2 diabetes really a coronary heart disease risk equivalent?

Authors:  Christoph H Saely; Heinz Drexel
Journal:  Vascul Pharmacol       Date:  2013-05-20       Impact factor: 5.773

7.  Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey.

Authors:  Bin Zhang; Joe Menzin; Mark Friedman; Jonathan R Korn; Russel T Burge
Journal:  Curr Med Res Opin       Date:  2008-08-12       Impact factor: 2.580

Review 8.  [After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9].

Authors:  M Abifadel; J-P Rabès; C Boileau; M Varret
Journal:  Ann Endocrinol (Paris)       Date:  2007-03-27       Impact factor: 2.478

9.  Molecular basis for LDL receptor recognition by PCSK9.

Authors:  Hyock Joo Kwon; Thomas A Lagace; Markey C McNutt; Jay D Horton; Johann Deisenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

10.  Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels.

Authors:  Rui-Xing Yin; Dong-Feng Wu; Lin Miao; Lynn Htet Htet Aung; Xiao-Li Cao; Ting-Ting Yan; Xing-Jiang Long; Wan-Ying Liu; Lin Zhang; Meng Li
Journal:  Cardiovasc Diabetol       Date:  2012-10-08       Impact factor: 9.951

View more
  19 in total

Review 1.  Next-generation gene discovery for variants of large impact on lipid traits.

Authors:  Elisabeth Rosenthal; Elizabeth Blue; Gail P Jarvik
Journal:  Curr Opin Lipidol       Date:  2015-04       Impact factor: 4.776

2.  Combined PCSK9 and APOE polymorphisms are genetic risk factors associated with elevated plasma lipid levels in a Thai population.

Authors:  Nutjaree Jeenduang; Sureerut Porntadavity; Smith Wanmasae
Journal:  Lipids       Date:  2015-04-22       Impact factor: 1.880

3.  Preliminary genome wide screening identifies new variants associated with coronary artery disease in Indian population.

Authors:  Keshavamurthy Ganapathy Bhat; Vivek Singh Guleria; Ratheesh Kumar J; Garima Rastogi; Varun Sharma; Anuka Sharma
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

4.  Relationships between genetic polymorphisms of E670G in PCSK9 gene and coronary artery disease: a meta-analysis.

Authors:  Dilare Adi; Xiang Xie; Fen Liu; Yi-Tong Ma; Mayila Abudoukelimu; Yun Wu; Yong An; Yi-Ning Yang; Xiao-Mei Li; Zhen-Yan Fu; Yong-Tao Wang; Bang-Dang Chen
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 5.  Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Anwar Santoso; Yulianto Yulianto; Hendra Simarmata; Abhirama Nofandra Putra; Erlin Listiyaningsih
Journal:  Int J Angiol       Date:  2021-02-18

6.  Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.

Authors:  Dengfeng Han; Jianhua Ma; Xiaoning Zhang; Jian Cai; Jinlan Li; Tuerhong Tuerxun; Chenguang Hao; Lei Du; Jing Lei
Journal:  Med Sci Monit       Date:  2014-09-30

7.  The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.

Authors:  Gaojun Cai; Bifeng Zhang; Ganwei Shi; Weijin Weng; Chunyan Ma; Yanbin Song; Ji Zhang
Journal:  Lipids Health Dis       Date:  2015-11-17       Impact factor: 3.876

8.  The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis.

Authors:  Anthony Au; Lyn R Griffiths; Kian-Kai Cheng; Cheah Wee Kooi; Looi Irene; Loo Keat Wei
Journal:  Sci Rep       Date:  2015-12-15       Impact factor: 4.379

9.  What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis.

Authors:  Chengfeng Qiu; Pingyu Zeng; Xiaohui Li; Zhen Zhang; Bingjie Pan; Zhou Y F Peng; Yapei Li; Yeshuo Ma; Yiping Leng; Ruifang Chen
Journal:  Lipids Health Dis       Date:  2017-06-12       Impact factor: 3.876

10.  Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke.

Authors:  Abhiram S Rao; Daniel Lindholm; Manuel A Rivas; Joshua W Knowles; Stephen B Montgomery; Erik Ingelsson
Journal:  Circ Genom Precis Med       Date:  2018-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.